Estrella Immunopharma Inc

For the period ended Mar 31, 2024. Filed May 15, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

ESLA$0.75+45.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Balance Sheets

As of March 31, 2024 · As of June 30, 2023
(Unaudited)
Current Assets
Current assets:
Cash and cash equivalent		$4,727,290	$2,479,146
Prepaid expenses and other receivable		406,110	-
Prepaid expenses, related party		3,500,000	-
Extension note receivable		-	273,066
Total current assets		8,633,400	2,752,212
Other Assets
Deferred transaction costs		-	276,187
Total Assets		$8,633,400	$3,028,399
Liabilities, Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable - related party	$	-	$9,333,146
Other payables and accrued liabilities		89,413	398,781
Accrued liability - related party		4,000	22,000
Franchise tax payables		4,359	4,297
Income tax payables		40,719	-
Total current liabilities		138,491	9,758,224
Non-current liabilities:
Other liability		-	12,725
Total non-current liabilities		-	12,725
Total Liabilities		138,491	9,770,949
Commitments and Contingencies (Note 7)
Preferred Stock*
Series A Preferred Stock, $0.0001 par value, 15,000,000 shares authorized; 0 and 1,203,695 shares issued and outstanding as of March 31, 2024 and June 30, 2023, respectively		-	5,000,000
Series AA Preferred Stock, $0.0001 par value, 105,000,000 shares authorized; 0 and 25,277,591 shares issued and outstanding as of March 31, 2024 and June 30, 2023, respectively		-	-
Stockholders’ Equity (Deficit):
Common stock, $0.0001 par value; 250,000,000 shares authorized; 36,610,870 and 978,243 shares issued as of March 31, 2024 and June 30, 2023, respectively;
36,535,980 and 978,243 shares outstanding as of March 31, 2024 and June 30, 2023, respectively*		3,661	98
Additional paid-in capital		24,124,543	445,905
Accumulated deficit		(15,549,204)	(12,188,553)
Treasury stock, at cost 74,890 and 0 shares as of March 31, 2024 and June 30, 2023, respectively		(84,091)	-
Total Stockholders’ Equity (Deficit)		8,494,909	(11,742,550)
Total Liabilities, Preferred Stock and Stockholders’ Equity (Deficit)		$8,633,400	$3,028,399

*	Giving retroactive effect to reverse recapitalization effected on September 29, 2023 to reflect exchange ratio of approximately 0.2407 as described in Note 3

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.